Merck & Co. SG&A decreased by 6.9% to $2.70B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 5.8%, from $2.55B to $2.70B. Over 4 years (FY 2021 to FY 2025), SG&A shows an upward trend with a 2.7% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
How to read this metric
Increases may indicate aggressive marketing or expansion, while decreases often reflect cost-cutting measures or improved corporate efficiency.
Detailed definition
The sum of all direct and indirect selling expenses and all general and administrative expenses of a company. This inclu...
Peer comparison
Used to assess the 'leaness' of a company's corporate structure relative to its peers.
selling_general_and_administrativeHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $2.28B | $2.34B | $2.38B | $2.32B | $2.51B | $2.52B | $2.69B | $2.48B | $2.70B | $2.52B | $2.80B | $2.48B | $2.74B | $2.73B | $2.86B | $2.55B | $2.65B | $2.63B | $2.90B | $2.70B |
| QoQ Change | — | +2.4% | +2.1% | -2.6% | +8.1% | +0.3% | +6.6% | -7.7% | +9.0% | -6.8% | +11.3% | -11.4% | +10.3% | -0.3% | +4.8% | -10.9% | +3.8% | -0.6% | +10.1% | -6.9% |
| YoY Change | — | — | — | — | +10.1% | +7.9% | +12.7% | +6.7% | +7.6% | -0.0% | +4.4% | +0.2% | +1.4% | +8.4% | +2.1% | +2.8% | -3.3% | -3.6% | +1.3% | +5.8% |
Business Segments
| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Pharmaceutical | $1.51B | $1.52B | $1.67B | $1.40B | $1.46B | $1.47B | $1.55B | $1.33B |
| Animal Health | $270.00M | $268.00M | $294.00M | $260.00M | $284.00M | $277.00M | $304.00M | $282.00M |
| Total | $2.74B | $2.73B | $2.86B | $2.55B | $2.65B | $2.63B | $2.90B | $2.70B |
Animal Health, Pharmaceutical were previously reported and have since been discontinued or reclassified. Only currently active segments are shown in the chart.
SG&A at Other Companies
Frequently Asked Questions
- What is Merck & Co.'s sg&a?
- Merck & Co. (MRK) reported sg&a of $2.70B in Q1 2026.
- How has Merck & Co.'s sg&a changed year-over-year?
- Merck & Co.'s sg&a increased by 5.8% year-over-year, from $2.55B to $2.70B.
- What is the long-term trend for Merck & Co.'s sg&a?
- Over 4 years (2021 to 2025), Merck & Co.'s sg&a has grown at a 2.7% compound annual growth rate (CAGR), from $9.63B to $10.73B.
- What does sg&a mean?
- The day-to-day costs of running the business and marketing its products.